Yes, the FDA should look at suicide with SSRI treatment. The SSRIs should not be reviewed, however, with a categorical directive – to come to a conclusion regarding: are they “good or bad?”
Way to simple! – and SSRIs are saving lives everyday. So why should the FDA look at suicide in adults – and just what is the problem?
SSRIs are predictably bad if the comorbid, associated, diagnosis is not recognized and not treated in the correct sequence. What a mouthful. But those of you on board with CorePsychBlog missives already have heard this theme. Problems with good meds: one of my favorite subjects, has been for more than 15 years. And now I have seen thousands of SPECT scans that verify the challenges we face in finding the correct multiple diagnoses. Get it all right and SSRIs are not a problem. Pictures speak louder than words. But first an outline of the problems.
This brief outline will be amplified on in later posts. Previous posts here do cover some of these subjects. For now please think of these topics as a table of contents for the next series of posts. These are a brief list of comorbid conditions that occur with depression. If any of these problems are untreated, the SSRI can often amplify the depression and the impulsivity. More likely to suicide.
There are probably a few I am missing but this is start.
Let's just hope the FDA starts their SSRI review with just the first two above.
Stay tuned: psychiatry is coming out of the closet, these are real medical, real life and death matters.
2 Comments
Lyle-
We all team up to work too fast, no fault, no blame, just need to dig deeper. Also, the drugs work and are effective, – the challenge is understanding the underlying biology.
Chuck
Whoa!
We are complex creatures… one and all.
Ah those darn silver bullets, needed to be fired at the right spot, with the correct caliber, and velocity.
Too bad, many patients just want to feel better fast!
LL